Trial Profile
Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Tivozanib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 13 Mar 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2026.
- 13 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.
- 31 Aug 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2023.